Strella Biotechnology Continues Scaling Up

Katherine Sizov (right) and Malika Shukurova (left) earned the 2019 President’s Innovation Prize for their startup, Strella Biotechnology.

“Fruit hacking” startup Strella Biotechnology, founded by students and faculty advisors from the School of Engineering and Applied Science (SEAS) and the School of Arts and Sciences (SAS), tackles food waste by monitoring fruit ripeness. No stranger to media coverage, Strella and co-founder Katherine Sizov have previously been spotlighted for receiving the 2019 President’s Innovation Prize, which included $100,000 of financial support, a $50,000 living stipend for both awardees, and a year of dedicated co-working and lab space at the Pennovation Center. 

Recently, Michael Birnbaum of the Washington Post spoke with Sizov about the hard work and flexibility it took to propel the company’s successful scaling endeavors: Strella is now monitoring 15 percent of all U.S. apples.  

“Sizov, 24, wants to eliminate food waste one fruit at a time. In central Washington, it was an effort that required almost as much quick footwork as the épée squad she captained as a championship fencer in college. One moment, she was trying to beam the sensor’s WiFi signal through the reception black hole of millions of apples, which cause transmission issues because of their high water content. The next, she was sitting down with laconic apple growers with orchards planted generations ago, trying to convince them she could help them avoid wasted fruit. By day’s end, she might be folding her 6-foot frame into the passenger seat of a rental car, balancing her laptop on her knees and trying to win over Silicon Valley investors on Zoom calls using skills she had picked up partly by watching YouTube tutorials.”

Read Michael Birnbaum’s Fighting food waste, one apple at a time” for more about Sizov’s motivation, background and process.

Strella Biotechnology was founded by Penn alumna Katherine Sizov (Bio 2019) and was initially developed in the George H. Stephenson Foundation Educational Laboratory, the biomakerspace and primary teaching lab of the Department of Bioengineering. Sizov and Penn Bioengineering alumna Malika Shukurova (BSE 2019) won a President’s Innovation Prize in 2019. Read more BE blog stories featuring Strella Biotechnology.

Strella Biotechnology Featured in Philly Mag

NextUp, a regular feature of Philadelphia Magazine that “highlights the local leaders, organizations and research shaping the Greater Philadelphia region’s life sciences ecosystem,” ran a profile of Philly-based agricultural startup Strella Biotechnology. Founded by Penn alumna Katherine Sizov (Bio 2019) and winner of a 2019 President’s Innovation Prize, Strella Biotech seeks to reduce food waste through innovative biosensors, and was initially developed in the George H. Stephenson Foundation Educational Laboratory, the biomakerspace and primary teaching lab of the Department of Bioengineering.

Sizov says the coronavirus pandemic has made the volatility of grocery stores’ offerings even more apparent. Last April, the Produce Marketing Association estimated that nearly $5 billion of fresh fruits and vegetables had gone to waste in the first month of the pandemic due to the complex supply chain’s inability to quickly redirect shipping and distribution. ‘In a way, I think COVID-19 has helped us realize how delicate and fragile supply chains are,’ she says. ‘We are working to create better, stronger supply chains that are economically and environmentally sustainable for everyone involved — researchers, growers, packagers, distributors, retailers, and consumers.'”

Read “NextUp: The Philly Startup Using Biosensors to Combat Food Waste and Improve Supply Chains” in Philly Mag.

Read more BE blog stories featuring Strella Biotechnology.

Bioengineering Graduate Gabriel DeSantis Awarded Fulbright Grant

Gabriel DeSantis (BSE 2020, MSE 2021)

Congratulations to recent Penn Bioengineering graduate Gabriel DeSantis on being awarded a Fulbright grant for the 2021-22 academic year:

“The Fulbright Program is the United States government’s flagship international educational exchange program, awarding grants to fund as long as 12 months of international experience.

‘As an avenue for building cross-cultural understanding, the U.S. Student Fulbright Program is an unparalleled opportunity for American students to represent our country and our University across the world,’ says Jane Morris, executive director of Penn’s Center for Undergraduate Research and Fellowships, which supports applicants. ‘We are so proud of all our Penn Fulbright students who will be contributing to this important mission through their study, research, and English teaching as Fulbrighters.’

Gabriel DeSantis, from Wellesley, Massachusetts, received his bachelor’s degree from Penn Bioengineering in 2020 and will graduate in May with a master’s degree in bioengineering from the School of Engineering and Applied Science. He was awarded a Fulbright to conduct research in Portugal at the International Iberian Nanotechnology Laboratory. There he will be creating a 3D bio-printed model to optimize the texture and nutritional profiles of cultivated meat. At Penn his academic interests included biology, food science, and sustainability, which he hopes to use to develop new systems of food production. On campus, DeSantis was a Penn Abroad Leader and board member of the Graduate Association of Bioengineers. He is a past chair of the Mask and Wig Club. He currently works as a research assistant for Allevi, a Philadelphia-based bioprinting company at Pennovation Works.”

Read the full list of Fulbright awardees in Penn Today.

Penn Bioengineering’s Tsourkas Lab and Penn Start-up AlphaThera Awarded $667,000 SBIR Phase II Grant to Improve COVID-19 Detection Assays

To combat the COVID-19 pandemic caused by the SARS-CoV2 virus, Dr. Andrew Tsourkas’s Targeted Imaging Therapeutics and Nanomedicine (Titan) Lab in Penn Bioengineering, in collaboration with the Penn-based startup, AlphaThera, was recently awarded a $667,000 SBIR Phase II Grant Extension to support its efforts in commercializing COVID-19 detection technology. The grant supports work to address the growing need for anti-viral antibody testing. Specifically, the Tsourkas Lab and AlphaThera hope to leverage their expertise with antibody conjugation technologies to reduce the steps and complexity of existing detection assays to enable greater production and higher sensitivity tests. AlphaThera was founded in 2016 by Andrew Tsourkas, PhD, Professor of Bioengineering and James Hui, MD, PhD, a graduate of the Perelman School of Medicine and Penn Bioengineering’s doctoral program.

During this pandemic it is crucial to characterize disease prevalence among populations, understand immunity, test vaccine efficacy and monitor disease resurgence. Projections have indicated that millions of daily tests will be needed to effectively control the virus spread. One important testing method is the serological assay: These tests detect the presence of SARS-CoV2 antibodies in a person’s blood produced by the body’s immune system responding to infection. Serological tests not only diagnose active infections, but also establish prior infection in an individual, which can greatly aid in forecasting disease spread and contact tracing. To perform the serological assays for antibody detection, well-established immunoassay methods are used such as ELISA.

A variety of issues have slowed the distribution of these serological assays for antibody testing. The surge in demand for testing has caused shortages in materials and reagents that are crucial for the assays. Furthermore, complexity in some of the assay formats can slow both production and affect the sensitivity of test results. Recognizing these problems, AlphaThera is leveraging its novel conjugation technology to greatly improve upon traditional assay formats.

With AlphaThera’s conjugation technology, the orientation of antibodies can be precisely controlled so that they are aligned and uniformly immobilized on assay detection plates. This is crucial as traditional serological assays often bind antibodies to plates in a non-uniform manner, which increases variability of results and reduces sensitivity. See Fig 1 below. With AlphaThera’s uniform antibody immobilization, assay specificity could increase by as much as 1000- fold for detection of a patient’s SaRS-CoV2 antibodies.

Fig 1: Uniform vs Non-Uniform Immobilized Antibodies on Surface: Top is AlphaThera improvement, showing how antibodies would be uniformly immobilized and oriented on a plate for detection. Bottom is how many traditional serological assays immobilize antibodies, resulting in variability of results and lower specificity.

Furthermore, AlphaThera is addressing the shortage of assay reagents, specifically secondary antibody reagents, by removing certain steps from traditional serological assays. Rather than relying on secondary antibodies for detection of the patient antibodies, AlphaThera’s technology can label the patient SaRS-CoV2 primary antibodies directly in serum with a detection reagent. This eliminates several processing steps, reducing the time of the assay by as much as 50%, as well as the costs.

The Tsourkas Lab and AlphaThera have initiated their COVID-19 project, expanding into the Pennovation Center and onboarding new lab staff. Other antibody labeling products have also become available and are currently being prepared for commercialization. Check out the AlphaThera website to learn more about their technology at https://www.alphathera.com.

NIH SBIR Phase II Grant Extension— 5-R44-EB023750-03 (PI: Yu)  — 10/07/2020 – 10/07/2021

Week in BioE (February 21, 2019)

by Sophie Burkholder

Detecting Infectious Diseases with Paper-Based Devices

Dr. Linnes’ paper device. Image used courtesy of Erin Easterling, Purdue College of Engineering.

Despite great advancements in diagnostics technology over the past few decades, patient accessibility to these technologies remains one of the biggest challenges of the field today. Particularly in low-resource areas, even simple processes can end up taking weeks or months to return results from tests that are normally completed in days. But what if these tests could be simplified to smaller, at-home tests based on properties of microfluidics – something like a pregnancy test but for infectious diseases like HIV?

Jacqueline Linnes, Ph.D., and her team of researchers at Purdue University are working towards finding a way to do just that by creating paper-based devices that use microfluidics to help carry out the necessary diagnostic tests. Specifically, her lab designed such a paper-based system that can detect HIV nucleic acids within 90 minutes of receiving a drop of patient blood. The success of this design shows promise for producing devices for diseases whose diagnostics process involve similar pathways of pathogen detection, opening the door to more applications of at-home tests based in the properties of paper microfluidics.

Here at Penn, undergraduate bioengineering students enrolled in the two-semester laboratory course Bioengineering Modeling, Analysis, and Design (BE 309 & BE 310) have the chance to create their own models of paper microfluidics delivery systems based on given time constraints in a multi-step process. Though the students’ challenge only involves water as a substrate, Linnes’ research demonstrates the later implications of studying fluid flow through a medium as cheap and accessible as paper.

Watch the video below demonstrating Dr. Linnes’ device:

Funding for Cancer Research in Tumor Mimicry and Imaging

Two of the deadliest forms of cancer today are breast cancer and pancreatic cancer, with the latter having a five-year survival rate of only about 8%. Because cancer treatments are often adjusted according to a unique patient-to-patient basis, learning how to improve predictions of tumor behavior could help determine proper therapies sooner.

Chien-Chi Lin, Ph.D., an associate professor of biomedical engineering at Indiana University – Purdue University Indianapolis, recently received a grant from the National Institute of Health to advance his research in pancreatic cancer treatment. His project under the grant involves the development of bio-inspired, responsive, and viscoelastic (BRAVE) cell-laden hydrogels to help understand cell interactions in pancreatic ductal adenocarcinoma, which is the most common form of malignancy in the pancreas. These hydrogels mimic tumor tissue, as well as model tumor development over time, helping to eventually find better ways of treating pancreatic cancer.

In other news surrounding cancer-related research, a team of researchers led by Kenneth Tichauer, Ph.D., at the Illinois Institute of Technology won the university’s Nayar Prize for their development of the Agent-Dependent Early Photon Tomography (ADEPT) Cancer Imager, a machine designed to find early tumor development in the lymph nodes of breast cancer patients. Through the use of a special dyeing process that now dyes the entire lymph node, providing a sharper image that allows for a quicker discovery of smaller tumors.

Penn’s Women in Computer Science (WiCS) Hosts FemmeHacks

Penn President Amy Gutmann and Penn Engineering Dean Vijay Kumar stopped by FemmeHacks at the Pennovation Center Feb. 9. The annual event is a beginner-friendly collegiate hackathon for women-identifying people with an interest in computer programming, and featured a day of all-levels workshops Feb. 8. The event is sponsored by Penn’s Women in Computer Science student organization.

Though the event is not specifically tailored towards applications in bioengineering, skills relating to coding and software development are increasingly important for those interested in pursuing a career in medical device design. In fact, in the evaluation of new medical devices, the FDA often focuses more on software over hardware, as the former is associated with more security liabilities, due to its relative novelty.

Read the full story and see pictures on FemmeHacks on Penn Today.

People & Places

In December, the department of biomedical engineering at the University of Alabama at Birmingham received the Ruth L. Kirschstein National Research Service Awards Institutional Research Training Grant, which will support predoctoral students enrolled in the university’s biomedical engineering graduate programs. The department plans to use the grant for research in cardiovascular tissue engineering.

Case Western Reserve University and Cleveland Clinic announced the launch of an alliance last year with the goal of creating better synergy across the two renowned institutions, hoping to provide more opportunities for students with interest in medicine at all levels, from high school to postdoctoral education. Though researchers from both institutions frequently partner on projects, this new alliance will create a more structured platform for future collaborations.

We would like to commend Steven George, M.D./Ph.D., on his new position as the chair of the Department of Biomedical Engineering at the University of California at Davis. His research involves the development of “organ-on-a-chip” technologies using stem cells and microfluidics to mimic human organ functions of vascularized cardiac, tumor, and pancreatic tissues.

Finally, we want to congratulate Paul Yock, M.D., on his being chosen to receive the National Academy of Engineering’s 2019 Fritz J. and Dolores H. Russ Prize. The prize honors two of Dr. Yock’s inventions from his research in interventional cardiology, one of which is Rapid Exchange, which is a kind of stenting and balloon angioplasty system. Dr. Yock is the Martha Meier Weiland Professor in the School of Medicine and Professor of Bioengineering.